A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2018 Status changed from active, no longer recruiting to completed.
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.